OTCMKTS:JCRRF JCR Pharmaceuticals (JCRRF) Stock Price, News & Analysis $3.73 0.00 (0.00%) As of 10/23/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartNews and Trends About JCR Pharmaceuticals Stock (OTCMKTS:JCRRF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get JCR Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.73▼$3.7350-Day Range$3.32▼$3.7352-Week Range$3.15▼$3.73VolumeN/AAverage Volume260 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview JCR Pharmaceuticals Co., Ltd. is a Japan-based biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company’s research programs include biologics, enzyme replacement therapies, growth hormone products, and regenerative medicine, with an emphasis on applying biotechnology to improve patient care. JCR’s portfolio includes therapies for rare lysosomal storage disorders and pediatric diseases. Its pabinafusp alfa product, marketed in Japan as IZCARGO, uses the company’s J-Brain Cargo platform, which is designed to help transport therapeutic proteins across the blood-brain barrier. JCR also develops additional investigational treatments based on this technology for neurological and other disorders. Founded in 1975 and headquartered in Ashiya, Hyogo, Japan, JCR primarily serves the Japanese market while pursuing international development and commercialization opportunities through partnerships and licensing arrangements. The company’s operations combine research and development, manufacturing, and commercialization of specialty pharmaceutical products.AI Generated. May Contain Errors. Read More Receive JCRRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for JCR Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JCRRF Stock News HeadlinesJCR Pharmaceuticals (JCRRF) Projected to Announce Earnings on ThursdayOctober 22, 2026 | americanbankingnews.comJCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter SyndromeOctober 14, 2026 | businesswire.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 27 at 1:00 AM | Porter & Company (Ad)Italfarmaco and JCR Pharmaceuticals Enter into Exclusive License Agreement for the Development and Potential Commercialization of Novel Investigational Therapy for Hunter Syndrome in the United States, Europe, and Latin AmericaOctober 2, 2026 | businesswire.comJCR Pharmaceuticals Deepens Fucosidosis Research With New Long-Term Patient StudyAugust 5, 2026 | tipranks.comJCR Pharmaceuticals Completes Restricted Stock Compensation TransactionJuly 22, 2026 | tipranks.comJCR Pharmaceuticals Receives Marketing Authorization in the United Arab Emirates for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter SyndromeJuly 21, 2026 | businesswire.comJCR Pharmaceuticals Sets 2026–2027 Timeline to Launch Givinostat for Duchenne Muscular Dystrophy in JapanJuly 14, 2026 | tipranks.comSee More Headlines JCRRF Stock Analysis - Frequently Asked Questions How have JCRRF shares performed this year? JCR Pharmaceuticals' stock was trading at $4.75 at the start of the year. Since then, JCRRF shares have decreased by 21.5% and is now trading at $3.73. How do I buy shares of JCR Pharmaceuticals? Shares of JCRRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today10/26/2026Next Earnings (Estimated)10/29/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:JCRRF CIKN/A Webwww.jcrpharm.co.jp Phone81 7 9732 8591FaxN/AEmployees934Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (OTCMKTS:JCRRF) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our Partners80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredWould Anthropic IPO Burst the Bubble?The biggest IPO in history is likely just weeks away… Anthropic, the company behind Claude AI, is rumoured ...Crypto 101 Media | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding JCR Pharmaceuticals Co., Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share JCR Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
